WallStSmart

Alcon AG (ALC)vsStevanato Group SpA (STVN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 777% more annual revenue ($10.40B vs $1.19B). STVN leads profitability with a 11.8% profit margin vs 9.4%. ALC appears more attractively valued with a PEG of 1.70. STVN earns a higher WallStSmart Score of 51/100 (C-).

ALC

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 5.0Value: 7.3Quality: 7.3
Piotroski: 4/9

STVN

Buy

51

out of 100

Grade: C-

Growth: 4.7Profit: 6.5Value: 4.7Quality: 6.3
Piotroski: 4/9Altman Z: 2.39
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-489.8%)

Margin of Safety

-489.8%

Fair Value

$13.46

Current Price

$75.26

$61.80 premium

UndervaluedFair: $13.46Overvalued
STVNSignificantly Overvalued (-262.8%)

Margin of Safety

-262.8%

Fair Value

$4.30

Current Price

$14.18

$9.88 premium

UndervaluedFair: $4.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

STVN2 strengths · Avg: 8.0/10
Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.9%8/10

Strong operational efficiency at 20.9%

Areas to Watch

ALC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
4.5%3/10

ROE of 4.5% — below average capital efficiency

EPS GrowthGrowth
-22.2%2/10

Earnings declined 22.2%

STVN3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.8%4/10

4.8% revenue growth

EPS GrowthGrowth
0.3%4/10

0.3% earnings growth

PEG RatioValuation
3.572/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Debt/Equity, Price/Book.

Bull Case : STVN

The strongest argument for STVN centers on Price/Book, Operating Margin.

Bear Case : ALC

The primary concerns for ALC are PEG Ratio, P/E Ratio, Return on Equity.

Bear Case : STVN

The primary concerns for STVN are Revenue Growth, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

ALC carries more volatility with a beta of 0.70 — expect wider price swings.

ALC is growing revenue faster at 8.6% — sustainability is the question.

ALC generates stronger free cash flow (489M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

STVN scores higher overall (51/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Stevanato Group SpA

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Stevanato Group SpA (STVN) is a leading global provider of advanced drug delivery systems, specializing in integrated solutions tailored for the pharmaceutical and biotechnology sectors. The company excels in the design and manufacturing of glass and polymer packaging for injectable medications, improving efficiency and reliability in the drug delivery process. With a strong commitment to quality and sustainability, Stevanato is well-positioned to benefit from the growing biopharmaceutical market, making it an attractive prospect for institutional investors looking to invest in healthcare innovation and technology advancement.

Want to dig deeper into these stocks?